C07D 241/52
Oxygen atoms
C07D241/52 (Oxygen atoms) appears on 173 US grants and 76 published applications in this corpus.
Search patents in C07D- Granted patents
- 173
- Published applications
- 76
- Assignees
- 95
- Inventors
- 337
- Latest grant
- 16 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 17 | 0 |
| 1977 | 7 | 0 |
| 1978 | 4 | 0 |
| 1979 | 1 | 0 |
| 1980 | 5 | 0 |
| 1981 | 4 | 0 |
| 1982 | 7 | 0 |
| 1983 | 6 | 0 |
| 1984 | 0 | 0 |
| 1985 | 3 | 0 |
| 1986 | 2 | 0 |
| 1987 | 7 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 4 | 0 |
| 1993 | 0 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 9 | 0 |
| 1998 | 11 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 2 |
| 2002 | 2 | 2 |
| 2003 | 5 | 5 |
| 2004 | 4 | 3 |
| 2005 | 3 | 5 |
| 2006 | 0 | 2 |
| 2007 | 2 | 2 |
| 2008 | 1 | 4 |
| 2009 | 3 | 4 |
| 2010 | 2 | 5 |
| 2011 | 3 | 3 |
| 2012 | 2 | 3 |
| 2013 | 3 | 5 |
| 2014 | 5 | 5 |
| 2015 | 3 | 4 |
| 2016 | 1 | 1 |
| 2017 | 3 | 4 |
| 2018 | 2 | 2 |
| 2019 | 2 | 4 |
| 2020 | 2 | 3 |
| 2021 | 4 | 6 |
| 2022 | 4 | 0 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Substituted phenazines and methods of treating cancer and bacterial diseases16 Apr 2024US 11,958,842 B2Adjutec Pharma AS
- Piperazine-2,5-diones as TGF-beta inhibitors22 Nov 2022US 11,505,531 B2Southern Research Institute
- (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases20 Sep 2022US 11,447,497 B2Histogen, Inc.
- Quaternary heteroatom containing compounds19 Jul 2022US 11,390,585 B2California Institute of Technology
- Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease19 Apr 2022US 11,306,063 B2Commissariat A L' Energie Atomique Et Aux Energies Alternatives
- 3,4-dihydroquinoxaline-2-carboximide derivative compound and pharmaceutical composition comprising same for preventing or treating cancer disease3 Jul 2025US 2025/0214947 A1Cureverse Incorporated
- Quaternary heteroatom containing compounds30 Mar 2023US 2023/0098847 A1California Institute of Technology
- Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection2 Dec 2021US 2021/0371388 A1Baruch S. Blumberg Institute
- Piperazine-2,5-diones as tgf-beta inhibitors21 Oct 2021US 2021/0323933 A1The UAB Research Foundation
- Substituted phenazines and methods of treating cancer and bacterial diseases23 Sep 2021US 2021/0292313 A1
Most cited
By later US patents
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases219US 6,482,834 B2Aventis Pharmaceuticals Inc. · 2002
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases207US 6,245,760 B1Aventis Pharmaceuticals Products Inc. · 2001